CHROMADEX CORPORATION

(CDXC)
  Report
Delayed Nasdaq  -  04:00 2022-06-29 pm EDT
1.750 USD   -2.23%
06/24CHROMADEX CORPORATION(NASDAQCM : CDXC) dropped from Russell 2500 Index
CI
06/24CHROMADEX CORPORATION(NASDAQCM : CDXC) dropped from Russell 2000 Growth Index
CI
06/24CHROMADEX CORPORATION(NASDAQCM : CDXC) dropped from Russell 2500 Growth Index
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ChromaDex : May 2022 Investor Presentation

05/23/2022 | 05:58pm EDT

Investor Presentation

Rob Fried

Chief Executive Officer

Kevin Farr

Chief Financial Officer

Nasdaq: CDXC | May 2022

ChromaDex Investment Highlights

  • Leader in the rapidly growing NAD+ market for healthy aging
  • Proven and proprietary NAD+ boosting supplement supported by 20 clinical trials
  • Strong revenue growth (34% CAGR(1)) driven by e-commerce and strong gross margins (61.5% in 2021)
  • Strategic partnerships to grow global distribution footprint with focus on Asia Pacific region
    1. Recent agreement to form Joint Venture to further expand in China
  • Significant opportunity driven by expanded benefit claims and product innovation

2

(1) CAGR calculated for the 2017-2021 calendar years period

Proven & Proprietary NAD+ Boosting Supplement

Benefitsof Tru Niagen®:

Patented · Proven · Trusted · Safe

20 published human clinical studies

30+ owned and licensed patents(1)

$85MM+ of third-party research on Niagen®

~$170B in total global addressable vitamins and supplements market, growing 5% annually(2)

Multi award winner

Tru Niagen® is the most efficient way to safely elevate NAD+

*Statements have not been evaluated by FDA

3

(1)

Related to Nicotinamide Riboside (NR).

(2)

ChromaDex estimates. See slide 6 for details.

Steady E-commerce Growth and Strong Gross Margins

Impressive historical revenue growth and significant gross margin expansion

Total 2021 net sales reached $67.4MM with $56.7MM in Tru Niagen® sales. E-commerce represents 62% of the business.

Gross margin increase from 49.4% to 61.5% since strategic pivot

to focus on consumer product, Tru Niagen®

138%

CAGR

34.5

41.8

27.5

15.0

1.3

2017

2018

2019

2020

2021

Annual e-commerce net sales

($ millions)

45.0

61.5%

62.0%

59.5%

40.0

55.7%

52.0%

50.9%

35.0

49.4%

42.0%

30.0

25.0

32.0%

20.0

35.3

41.5

22.0%

15.0

25.8

12.0%

10.0

16.1

10.5

2.0%

5.0

0.0

-8.0%

2017

2018

2019

2020

2021

Annual gross profit

($ millions)

4

Expanding Global Distribution Footprint with Strategic Partners

Key E-Commerce Platforms

Tru Niagen® Sales Mix(1)

Key B2B / Distribution Partners(2)

Key Niagen® Ingredient Partners(3)

Domestic

International

TruNiagen.com

Amazon

Amazon

Tmall

Pro.truniagen.com (HCP)

JD.com

69%

31%

(1)

Based on full year 2021 net sales.

5

(2)

SinoPharm partnership is new, with sales expected in 2022.

(3)

W.R. Grace is an exclusive supplier of Niagen® to ChromaDex.

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

ChromaDex Corp. published this content on 23 May 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 May 2022 21:57:10 UTC.


© Publicnow 2022
All news about CHROMADEX CORPORATION
06/24CHROMADEX CORPORATION(NASDAQCM : CDXC) dropped from Russell 2500 Index
CI
06/24CHROMADEX CORPORATION(NASDAQCM : CDXC) dropped from Russell 2000 Growth Index
CI
06/24CHROMADEX CORPORATION(NASDAQCM : CDXC) dropped from Russell 2500 Growth Index
CI
06/24CHROMADEX CORPORATION(NASDAQCM : CDXC) dropped from Russell 3000 Growth Index
CI
06/24CHROMADEX CORPORATION(NASDAQCM : CDXC) dropped from Russell 2000 Index
CI
06/24CHROMADEX CORPORATION(NASDAQCM : CDXC) dropped from Russell 2000 Dynamic Index
CI
06/24CHROMADEX CORPORATION(NASDAQCM : CDXC) dropped from Russell Small Cap Comp Growth Index
CI
06/24CHROMADEX CORPORATION(NASDAQCM : CDXC) dropped from Russell 3000E Index
CI
06/24CHROMADEX CORPORATION(NASDAQCM : CDXC) dropped from Russell 3000E Growth Index
CI
06/24CHROMADEX CORPORATION(NASDAQCM : CDXC) dropped from Russell 3000 Index
CI
More news
Analyst Recommendations on CHROMADEX CORPORATION
More recommendations
Financials (USD)
Sales 2022 78,6 M - -
Net income 2022 -23,5 M - -
Net Debt 2022 - - -
P/E ratio 2022 -5,10x
Yield 2022 -
Capitalization 120 M 120 M -
Capi. / Sales 2022 1,53x
Capi. / Sales 2023 1,19x
Nbr of Employees 115
Free-Float 60,0%
Chart CHROMADEX CORPORATION
Duration : Period :
ChromaDex Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHROMADEX CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 1,75 $
Average target price 7,91 $
Spread / Average Target 352%
EPS Revisions
Managers and Directors
Robert N. Fried Chief Executive Officer & Director
Kevin M. Farr Chief Financial & Accounting Officer
Frank L. Jaksch Executive Chairman
Aron Erickson Vice President-Research & Development
Ben Shichman Chief Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
CHROMADEX CORPORATION-53.21%120
MODERNA, INC.-43.77%56 804
IQVIA HOLDINGS INC.-24.11%40 527
LONZA GROUP AG-33.77%39 234
SEAGEN INC.15.82%32 961
CELLTRION, INC.-11.11%18 726